# TRIM21 as a regulator of UVB- and cytosolic DNA-driven IFN responses in lupus

> **NIH NIH R56** · CEDARS-SINAI MEDICAL CENTER · 2022 · $367,400

## Abstract

Patients with systemic lupus erythematosus (SLE) experience photosensitivity, with exposure to ultraviolet light
(UV) often driving lupus flares, triggering symptoms like joint pain and fatigue, in addition to causing cutaneous
lesions. However, although the mechanism(s) linking UVB exposure to systemic effects are unclear, type I IFNs
are known to play a role. Our previous work has shown that the E3 ligase TRIM21 is a negative regulator of IFN
expression. Interestingly we observed that Trim21-/- mice develop spontaneous skin lesions in response to DNA
detection in the skin. This prompted us to investigate whether Trim21-/- mice were hyperresponsive to UV in
driving skin inflammation. Trim21-/- mice develop more severe skin inflammation in response to UVB compared
to wild type, as well as splenomegaly and enhanced levels of systemic IFNs. Regarding targets for TRIM21 in
regulating UVB-induced responses we have identified DDX41, a relatively under studied DNA sensor as a
potential target. We hypothesize that TRIM21 acts as a gatekeeper against systemic disease by preventing
uncontrolled systemic IFN responses driven by cytosolic DNA sensing, such as demonstrated in the UVB skin
model and that this may have implications for photosensitivity in SLE. To evaluate this, we propose the following:
Aim 1: Assess the role of TRIM21 in UVB-induced skin inflammation and how it contributes to systemic
changes. We will define what immune cells are key to systemic disease in the Trim21-/- mice and how STING-
and IFN-dependent and independent pathways mediate the drive the transition from local to systemic
inflammation in response to UVB in the absence of TRIM21.
Aim 2: Determine the role of TRIM21 and DDX41 in regulating cGAS-STING signaling in response to UVB.
We will investigate how TRIM21 and DDX41 is regulated downstream of UVB and ask how their loss alters the
composition, stability and function of the STING signalsome using a combination of biochemistry and proteomics.
Aim 3: Define how loss of TRIM21 contributes both cutaneous and systemic UVB-driven IFN responses.
Analysis of PBMCs and skin biopsies from SLE patients will determine how TRIM21 may contribute to
photosensitivity in SLE and the role of STING in driving these responses.
Impact: This project will determine the mechanisms underlying this hitherto unknown role of TRIM21 in
controlling UVB-driven systemic IFN responses and ask whether altered TRIM21-regulated pathways can
explain the link between UVB exposure and increased risk of lupus flare in SLE.

## Key facts

- **NIH application ID:** 10707577
- **Project number:** 1R56AR078279-01A1
- **Recipient organization:** CEDARS-SINAI MEDICAL CENTER
- **Principal Investigator:** Caroline Jefferies
- **Activity code:** R56 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $367,400
- **Award type:** 1
- **Project period:** 2022-09-23 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10707577

## Citation

> US National Institutes of Health, RePORTER application 10707577, TRIM21 as a regulator of UVB- and cytosolic DNA-driven IFN responses in lupus (1R56AR078279-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10707577. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*